TEST REPORT

8605 SW Creekside Place Beaverton, OR 97008 Phone: 503-466-2445 Fax: 503-466-1636



2018 08 08 222 S

Ordering Provider: Getuwell Clinic John Getuwell. MD

Samples Received 08/08/2018

Samples Collected Saliva - 08/05/18 06:05

Report Date 08/10/2018

Patient Name: Hormone Trio Patient Phone Number: 555 555 5555

Gender Female	Last Menses Unspecified	Heig Uns	ght pecified	Waist Unspecified
DOB 7/13/1958 (60 yrs)	Menses Status Postmenopausal	Wei g Uns	ght pecified	
TEST NAME	RESULTS 08/05/	18	RANGE	
Salivary Steroids				
Estradiol	2.2		0.8-12 pg/	mL Estrogen Rplcmnt (optimal 1.3-3.3)
Progesterone	833		200-3000	pg/mL Topical, Troche, Vag Pg (10-30mg)
Ratio: Pg/E2	379		Optimal: 1	00-500 when E2 1.3-3.3 pg/mL
Testosterone	33		16-55 pg/r	nL (Age Dependent)

<dL = Less than the detectable limit of the lab. N/A = Not applicable; 1 or more values used in this calculation is less than the detectable limit. H = High. L = Low.</p>

Therapies

1mg topical Biestrogen (80/20 E3 + E2) (compounded) (24 Hours Last Used)30mg topical Progesterone (compounded) (12 Hours Last Used)0.5mg topical Testosterone (compounded) (24 Hours Last Used) topical DHEA (compounded) (24 Hours Last Used)



TEST REPORT | Patient Reported Symptoms

Disclaimer: Symptom Categories below show percent of symptoms self-reported by the patient compared to total available symptoms for each category. For detailed information on category breakdowns, go to www.zrtlab.com/patient-symptoms.

SYMPTOM CATEGORIES	RESULTS 08/05/18
Estrogen / Progesterone Deficiency	2% 📕
Estrogen Dominance / Progesterone Deficiency	0%
Low Androgens (DHEA/Testosterone)	4%
High Androgens (DHEA/Testosterone)	10%
Low Cortisol	5%
High Cortisol	2%
Hypometabolism	0%
Metabolic Syndrome	2%

SYMPTOM CHE	CKLIST		MILD	MODERATE	SEVERE
Aches and Pains					
Acne					
Allergies		1			
Anxious		(ii)			
Bleeding Change	S	1			
Blood Pressure H		1			
Blood Pressure L					
Blood Sugar Low		1			
Body Temperatur		1			
Bone Loss					
Breast Cancer		1			
Breasts - Fibrocys	stic				
Breasts - Tender		1			
Chemical Sensitiv	vity	1 i i i i i i i i i i i i i i i i i i i			
Cholesterol High		1			
Constipation		10 C			
Depressed					
Fatigue - Evening]				
Fatigue - Morning]				
Fibromyalgia					
Foggy Thinking					
Goiter					
Hair - Dry or Brittl	le				
Hair - Increased F	Facial or Body				
Hair - Scalp Loss					
Headaches					
Hearing Loss					
Heart Palpitations	3				
Hoarseness					
Hot Flashes					
Incontinence					
Infertility					
Irritable					
Libido Decreased	1				
Memory Lapse					
Mood Swings					
Muscle Size Decr	reased				
Nails Breaking or	Brittle				
Nervous					
Night Sweats					
Numbness - Feet	or Hands				
CLIA Lic # 38D0960950 9/14/2018 10:27:53 AM	The above results and comments are for informational purposes only and are not to be construed as medical advice. Please consult your healthcare practitioner for	David I. Zava.	David T. Zava, Ph.D. Laboratory Director	ADM ALUSTECND. (Ordering	IcAllister, ND. 2 of 3 g Provider unless a specified on page 1)

purposes only and are not to be construed as medical advice. Please consult your healthcare practitioner for diagnosis and treatment.

Navid J. Zava. Laboratory Director

otherwise specified on page 1)

© 1998-2018 ZRT Laboratory, LLC. All rights reserved.

TEST REPORT | Patient Reported Symptoms continued

SYMPTOM CHECKLIST	MILD	MODERATE	SEVERE
Pulse Rate Slow			
Rapid Aging			
Rapid Heartbeat			
Skin Thinning			
Sleep Disturbed			
Stamina Decreased			
Stress			
Sugar Cravings			
Sweating Decreased			
Swelling or Puffy Eyes/Face			
Tearful			
Triglycerides Elevated			
Urinary Urge Increased			
Uterine Fibroids			
Vaginal Dryness			
Water Retention			
Weight Gain - Hips			
Weight Gain - Waist			

Lab Comments

Estradiol is within the observed range for physiological topical bi-estrogen replacement therapy, and within the observed range seen in most premenopausal women (1.3-3.3 pg/ml) without symptoms of estrogen imbalance. Symptoms of estrogen imbalance are minimal at this time, based on self-reporting, indicating that dosing and delivery of estrogens is optimal.

Progesterone is within luteal range with physiological (10-30 mg) topical progesterone supplementation. Progesterone is well balanced with estradiol (optimal Pg/E2 ratio) and symptoms of estrogen/progesterone imbalance (deficiency and excess) are minimal.

Testosterone is within expected range with physiological topical testosterone therapy. Symptoms of androgen deficiency and/or excess are minimal, indicating that dosing and delivery is appropriate and optimal.



David T. Zava, Ph.D.